Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis
The over-arching aim of CanProCo is to evaluate a spectrum of micro and macro factors (e.g., biological, micro-structural, demographic, clinical, environmental, epidemiological and health-systems) associated with the de novo onset and rate of multiple sclerosis (MS) disease progression over a 5 year period, and to assess how these factors relate to one another.
Overview
- Acronym
- CanProCo
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 2018 -
- General Information on Follow Up (profile, frequency)
-
The total study duration is 5 years and participants attend 6 visits over this period, once at baseline (i.e. study start), and again yearly for follow-ups.
- Recruitment Target
-
- Individuals
- Number of Participants
- 1,000
- Supplementary Information
-
The CanProCo study is comprised of a foundation cohort (N=950) of patient participants and a smaller group of control subjects (N=50). All study participants (N=1000) contribute basic clinical and epidemiological data. Half of the overall study population will contribute additional data in what are called sub-cohorts. The CanProCo sub-cohorts are as follows: early RRMS (N=200), early PPMS (N=100), enriched RIS (N=150), and healthy controls (N=50).
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Supplementary Information
The Canadian prospective cohort (CanProCo) study to understand progression in multiple sclerosis: rationale, aims, and study design. J. Oh, N. et al. ECTRIMS 2019 - Poster Session 2. Multiple Sclerosis Journal 2019 25:2_suppl, 357-580.
Timeline
Populations
CanProCo - Foundation cohort
The CanProCo foundation cohort is comprised of individuals aged 18-60 and having one of the following: relapsing remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS), disease onset within 10 years, primary progressive multiple sclerosis (PPMS), disease onset within 15 years, or diagnosis (any time) of radiologically isolated syndrome (RIS). Participants must be able to ambulate (i.e. walk) 100 meters independently or using a walking aid.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
60
- Countries
-
- Canada
- Canadian Provinces
-
- Alberta
- British Columbia
- Ontario
- Quebec
- Health Status
-
- Inclusion:
- Diagnosis of RRMS within 10 years of disease onset OR
- Diagnosis of CIS with high risk (i.e. confirmed dissemination in space [DIS] on MRI) of MS conversion, within 10 years of onset OR
- Diagnosis of PPMS within 15 years of disease onset OR
- Diagnosis of RIS (no restriction on timing of diagnosis)
- Expanded Disease Disability Scale (EDSS) score of 6.5 or less
- Exclusion:
- Previous or current treatment with chemotherapy for malignancy
- Other Criteria
-
- Inclusion:
- Speak/understand English or French to a reasonable degree
- Supplementary Information about selection criteria
-
Women who are pregnant may enroll into the foundation cohort.
Sources of Recruitment
- Specific Population
-
- Other specific population : Individuals living with MS, CIS, or RIS
- Supplementary Information
-
Participants are recruited from MS clinics at the following locations: Foothills Hospital (Calgary, Alberta), Kaye Edmonton Clinic (Edmonton, Alberta), UBC Hospital, Djavad Mowafaghian Centre for Brain Health (Vancouver, British Columbia), Centre Hospitalier de l’Université de Montréal (Montréal, Québec), and St. Michael’s Hospital (Toronto, Ontario).
Sample Size
- Number of Participants
- 950
- Supplementary information about number of participants
-
including embedded early RRMS, early PPMS and enriched RIS sub- cohorts
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | CanProCo - Foundation Cohort - Baseline |
|
2018 (October) | 2019 (September) | |
| 1 | CanProCo - Foundation Cohort - Visit 1 |
|
2019 (October) | 2020 (September) | |
| 2 | CanProCo - Foundation Cohort - Visit 2 |
|
2020 (October) | 2021 (September) | |
| 3 | CanProCo - Foundation Cohort - Visit 3 |
|
2021 (October) | 2022 (September) | |
| 4 | CanProCo - Foundation Cohort - Visit 4 |
|
2022 (October) | 2023 (September) | |
| 5 | CanProCo - Foundation Cohort - Visit 5 |
|
2023 (October) | 2024 (September) |
CanProCo - Foundation cohort (Enriched RIS)
The CanProCo enriched RIS sub-cohort is comprised of individuals aged 18-60 diagnosed with radiologically isolated syndrome (RIS). Participants must be able to ambulate (i.e. walk) 100 meters independently or using a walking aid.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
60
- Countries
-
- Canada
- Canadian Provinces
-
- Alberta
- British Columbia
- Ontario
- Quebec
- Health Status
-
- Inclusion:
- Diagnosis of RIS
- Expanded Disease Disability Scale (EDSS) score of 6.5 or less
- Exclusion:
- Human immunodeficiency virus (HIV) positive
- Previous or current treatment with chemotherapy for malignancy
- Other Criteria
-
- Inclusion:
- Speak/understand English or French to a reasonable degree
- Supplementary Information about selection criteria
-
Women who are pregnant may not enroll into the enriched RIS sub-cohort.
Sources of Recruitment
- Specific Population
-
- Other specific population : Individuals living with RIS
- Supplementary Information
-
Participants are recruited from MS clinics at the following locations: Foothills Hospital (Calgary, Alberta), Kaye Edmonton Clinic (Edmonton, Alberta), UBC Hospital, Djavad Mowafaghian Centre for Brain Health (Vancouver, British Columbia), Centre Hospitalier de l’Université de Montréal (Montréal, Québec), and St. Michael’s Hospital (Toronto, Ontario).
Sample Size
- Number of Participants
- 150
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | CanProCo - Foundation cohort (Enriched RIS) - Baseline |
|
|
2018 (October) | 2019 (September) |
| 1 | CanProCo - Foundation cohort (Enriched RIS) - Visit 1 |
|
|
2019 (October) | 2020 (September) |
| 2 | CanProCo - Foundation cohort (Enriched RIS) - Visit 2 |
|
|
2020 (October) | 2021 (September) |
| 3 | CanProCo - Foundation cohort (Enriched RIS) - Visit 3 |
|
|
2021 (October) | 2022 (September) |
| 4 | CanProCo - Foundation cohort (Enriched RIS) - Visit 4 |
|
|
2022 (October) | 2023 (September) |
| 5 | CanProCo - Foundation cohort (Enriched RIS) - Visit 5 |
|
|
2023 (October) | 2024 (September) |
CanProCo - Foundation cohort (Early RRMS)
The CanProCo early RRMS sub-cohort is comprised of individuals aged 18-60 with disease onset of relapsing remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) within the last 5 years, and who are treatment naïve or not treated with disease modifying therapy in the last 6 or more months. Participants must be able to ambulate (i.e. walk) 100 meters independently or using a walking aid.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
60
- Countries
-
- Canada
- Canadian Provinces
-
- Alberta
- British Columbia
- Ontario
- Quebec
- Health Status
-
- Inclusion:
- Diagnosis of RRMS within 5 years of disease onset
- Diagnosis of CIS with high risk (i.e. confirmed dissemination in space [DIS] on MRI) of MS conversion, within 5 years of onset
- Treatment naïve or not on disease modifying therapy ≥6 months
- Expanded Disease Disability Scale (EDSS) score of 6.5 or less
- Exclusion:
- Human immunodeficiency virus (HIV) positive
- Previous or current treatment with chemotherapy for malignancy
- Other Criteria
-
- Inclusion:
- Speak/understand English or French to a reasonable degree
- Supplementary Information about selection criteria
-
Women who are pregnant may not enroll into the early RRMS sub-cohort. At least 100 of participants from this sub-cohort must demonstrate “high” disease activity, as defined by the following: Occurrence of ≥2 relapses in the past year OR 1 relapse in the past year AND ≥10 T2 lesions AND ≥3 Gadolinium (Gad)+ lesion OR 1 relapse in the past year AND ≥10 T2 lesions AND ≥3 new T2 lesions in the past 1-2 years OR 1 relapse in the past year AND ≥10 T2 lesions and brainstem/spinal cord involvement (clinically or on MRI) OR 1 relapse in the past year with ≥10 T2 lesions with incomplete relapse recovery and EDSS ≥2.0 Note: Induction therapies (e.g., Mavenclad, Lemtrada) have continuous effects without the need for continuous dosing. Individuals EVER having received such treatments should be considered ON TREATMENT and cannot be enrolled into the early RRMS sub-cohort. They may, however, be enrolled before such a treatment is delivered. Note: Individuals EVER having received stem cell transplantation should be considered ON TREATMENT and cannot be enrolled into the early RRMS sub-cohort. They may, however, be enrolled before such a treatment is delivered.
Sources of Recruitment
- Specific Population
-
- Other specific population : Individuals living with RRMS or CIS
- Supplementary Information
-
Participants are recruited from MS clinics at the following locations: Foothills Hospital (Calgary, Alberta), Kaye Edmonton Clinic (Edmonton, Alberta), UBC Hospital, Djavad Mowafaghian Centre for Brain Health (Vancouver, British Columbia), Centre Hospitalier de l’Université de Montréal (Montréal, Québec), and St. Michael’s Hospital (Toronto, Ontario).
Sample Size
- Number of Participants
- 200
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | CanProCo - Foundation cohort (Early RRMS) - Baseline |
|
|
2018 (October) | 2019 (September) |
| 1 | CanProCo - Foundation cohort (Early RRMS) - Visit 1 |
|
|
2019 (October) | 2020 (September) |
| 2 | CanProCo - Foundation cohort (Early RRMS) - Visit 2 |
|
|
2020 (October) | 2021 (September) |
| 3 | CanProCo - Foundation cohort (Early RRMS) - Visit 3 |
|
|
2021 (October) | 2022 (September) |
| 4 | CanProCo - Foundation cohort (Early RRMS) - Visit 4 |
|
|
2022 (October) | 2023 (September) |
| 5 | CanProCo - Foundation cohort (Early RRMS) - Visit 5 |
|
|
2023 (October) | 2024 (September) |
CanProCo - Foundation cohort (Early PPMS)
The CanProCo early PPMS sub-cohort is comprised of individuals aged 18-60 with disease onset of primary progressive multiple sclerosis (PPMS) within the last 10 years. Participants must be able to ambulate (i.e. walk) 100 meters independently or using a walking aid.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
60
- Countries
-
- Canada
- Canadian Provinces
-
- Alberta
- British Columbia
- Ontario
- Quebec
- Health Status
-
- Inclusion:
- Diagnosis of PPMS within 10 years of disease onset
- Expanded Disease Disability Scale (EDSS) score of 6.5 or less
- Exclusion:
- Human immunodeficiency virus (HIV) positive
- Previous or current treatment with chemotherapy for malignancy
- Other Criteria
-
- Inclusion:
- Speak/understand English or French to a reasonable degree
- Supplementary Information about selection criteria
-
Women who are pregnant may not enroll into the early PPMS sub-cohort.
Sources of Recruitment
- Specific Population
-
- Other specific population : Individuals living with PPMS
- Supplementary Information
-
Participants are recruited from MS clinics at the following locations: Foothills Hospital (Calgary, Alberta), Kaye Edmonton Clinic (Edmonton, Alberta), UBC Hospital, Djavad Mowafaghian Centre for Brain Health (Vancouver, British Columbia), Centre Hospitalier de l’Université de Montréal (Montréal, Québec), and St. Michael’s Hospital (Toronto, Ontario).
Sample Size
- Number of Participants
- 100
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | CanProCo - Foundation cohort (Early PPMS) - Baseline |
|
|
2018 (October) | 2019 (September) |
| 1 | CanProCo - Foundation cohort (Early PPMS) - Visit 1 |
|
|
2019 (October) | 2020 (September) |
| 2 | CanProCo - Foundation cohort (Early PPMS) - Visit 2 |
|
|
2020 (October) | 2021 (September) |
| 3 | CanProCo - Foundation cohort (Early PPMS) - Visit 3 |
|
|
2021 (October) | 2022 (September) |
| 4 | CanProCo - Foundation cohort (Early PPMS) - Visit 4 |
|
|
2022 (October) | 2023 (September) |
| 5 | CanProCo - Foundation cohort (Early PPMS) - Visit 5 |
|
|
2023 (October) | 2024 (September) |
CanProCo - Healthy controls
The CanProCo healthy control sub-cohort is comprised of individuals aged 18-60 with no known neurological illness or history of traumatic brain injury.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
60
- Countries
-
- Canada
- Canadian Provinces
-
- Alberta
- British Columbia
- Ontario
- Quebec
- Health Status
-
- Exclusions:
- Previous traumatic brain injury, brain surgery, recent cancer treatment, dementia, stroke, or neurological or psychiatric (e.g., major depressive disorder) disease causing functional limitation.
- Human immunodeficiency virus (HIV) positive
- Previous or current treatment with chemotherapy for malignancy
- Other Criteria
-
- Inclusion:
- Speak/understand English or French to a reasonable degree
- Supplementary Information about selection criteria
-
Women who are pregnant may not enroll into the healthy control sub-cohort.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
- Specific Population
-
- Other specific population : Age- and sex-matched controls recruited (where possible) from spouses or family members of patient participants
- Supplementary Information
-
The rationale for selecting a healthy control sub-cohort is to serve as an age- and sex- matched control group for the patient (i.e. clinical) sub-cohorts. The age and sex distribution of the early RRMS, early PPMS, and enriched RIS sub-cohorts will be evaluated and healthy controls will be recruited to match this distribution.
Sample Size
- Number of Participants
- 50
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | CanProCo - Healthy controls - Baseline |
|
2018 (October) | 2019 (September) | |
| 1 | CanProCo - Healthy controls - Visit 1 |
|
|
2019 (October) | 2020 (September) |
| 2 | CanProCo - Healthy controls - Visit 2 |
|
|
2020 (October) | 2021 (September) |
| 3 | CanProCo - Healthy controls - Visit 3 |
|
|
2021 (October) | 2022 (September) |
| 4 | CanProCo - Healthy controls - Visit 4 |
|
|
2022 (October) | 2023 (September) |
| 5 | CanProCo - Healthy controls - Visit 5 |
|
|
2023 (October) | 2024 (September) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2024-02-27T12:50:15.813